Neurona Therapeutics announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its investigational therapy NRTX-1001 for the treatment of drug-resistant focal epilepsy. According to the company, this designation is intended to provide early and enhanced regulatory support for medicines that may offer major therapeutic advantages for patients with serious or unmet medical needs.
NRTX-1001 is described by the company as a regenerative cell therapy made from inhibitory neurons derived from human pluripotent stem cells. It is designed to restore neural network balance by delivering these neurons to targeted brain regions where seizures originate. The company said that NRTX-1001 has the potential to provide long-lasting seizure control and improved quality of life for patients who do not respond adequately to existing antiepileptic drugs or surgical interventions.
According to Neurona Therapeutics, the PRIME designation was granted based on encouraging preliminary clinical data from an ongoing Phase 1/2 trial in the United States. The company claims that early results have demonstrated favorable safety, tolerability, and reductions in seizure frequency among participants.
The company said that the designation will enable closer interaction with the EMA throughout the clinical development process, potentially expediting the path toward marketing authorization in the European Union. Neurona Therapeutics stated that it plans to advance the NRTX-1001 program through additional clinical studies in both the U.S. and Europe to further evaluate efficacy and durability of response in patients with focal epilepsy.
